Brain+
0.019
DKK
-2.06 %
Less than 1K followers
BRAINP
First North Denmark
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-2.06%
-4.04%
-39.35%
-59.27%
-59%
-56.98%
-97.35%
-
-98.61%
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.
Read moreMarket cap
12.4M DKK
Turnover
20.48K DKK
Revenue
200K
EBIT %
-5,830 %
P/E
-
Dividend yield-%
-
Financial calendar
28/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Brain+ A/S: Leading UK dementia care authority, Antony Hall, joins Brain+ as Strategic Advisor
Impala Nordic: Brain+ Podcast interview with Devika Wood, CEO
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools